Literature DB >> 36271406

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.

Baran Mollavelioglu1, Esin Cetin Aktas2, Neslihan Cabioglu1, Aykhan Abbasov1, Semen Onder3, Selman Emiroglu1, Mustafa Tükenmez1, Mahmut Muslumanoglu1, Abdullah Igci1, Gunnur Deniz2, Vahit Ozmen4.   

Abstract

High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated.The study included 32 patients who underwent surgery with a diagnosis of early-stage breast cancer between September 2018 and March 2020. TIL isolation was performed using a MACS tumor separation device and tumor separation kit. PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT expression of cytotoxic T and natural killer (NK) cells on TILs and peripheral blood lymphocytes (PBLs) were determined by flow cytometry.Patients with a high Ki-67 index, high TIL density, and HER-2 positivity were more likely to have increased CD16+CD56dim NK cells on TILs. Patients with T2 tumors were more likely to have increased expression of PD-1, LAG-3, and TIGIT on tumor-infiltrating CD8+ cytotoxic T cells than those with T1 tumors. PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3 expression of CD8+ T and CD16-CD56bright NK cells in TILs showed significant positive correlations with each other. PD1+CD8+, TIGIT+CD16+, and CTLA-4+CD56+ cells in PBLs and TILs were found to be negatively correlated, whereas only TIM-3+ expression of CD8+ T and CD16+CD56dim cells in PBLs and TILs showed positive correlations.Our results suggest that CD16+CD56dim NK cells on TILs may play a major role in the immune response against HER2-positive or highly proliferating breast tumors in patients with early-stage breast cancer. Furthermore, various ICRs were found to be highly co-expressed with each other on TILs, including PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT. These receptors may synergistically suppress the response to the tumor, which may trigger immune escape mechanisms in the early stage of carcinogenesis. However, ICR expressions other than TIM3 on PBLs were not found to accompany their counterparts on TILs.
© 2022. The Author(s).

Entities:  

Keywords:  CTLA-4; Early-stage breast cancer; LAG-3; NK; PD-1; TIGIT; TIL; TIM-3

Year:  2022        PMID: 36271406     DOI: 10.1186/s12957-022-02810-z

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   3.253


  21 in total

1.  Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Authors:  Carlos R Gil Del Alcazar; Sung Jin Huh; Muhammad B Ekram; Anne Trinh; Lin L Liu; Francisco Beca; Xiaoyuan Zi; Minsuk Kwak; Helga Bergholtz; Ying Su; Lina Ding; Hege G Russnes; Andrea L Richardson; Kirsten Babski; Elizabeth Min Hui Kim; Charles H McDonnell; Jon Wagner; Ron Rowberry; Gordon J Freeman; Deborah Dillon; Therese Sorlie; Lisa M Coussens; Judy E Garber; Rong Fan; Kristie Bobolis; D Craig Allred; Joon Jeong; So Yeon Park; Franziska Michor; Kornelia Polyak
Journal:  Cancer Discov       Date:  2017-06-26       Impact factor: 39.397

2.  LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII.

Authors:  Takumi Maruhashi; Il-Mi Okazaki; Daisuke Sugiura; Suzuka Takahashi; Takeo K Maeda; Kenji Shimizu; Taku Okazaki
Journal:  Nat Immunol       Date:  2018-10-22       Impact factor: 25.606

3.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  Makiko Ono; Hitoshi Tsuda; Chikako Shimizu; Sohei Yamamoto; Tatsuhiro Shibata; Harukaze Yamamoto; Taizo Hirata; Kan Yonemori; Masashi Ando; Kenji Tamura; Noriyuki Katsumata; Takayuki Kinoshita; Yuichi Takiguchi; Hideki Tanzawa; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2011-05-12       Impact factor: 4.872

4.  Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.

Authors:  Kristi Baker; Jonathan Lachapelle; Inti Zlobec; Tarek A Bismar; Luigi Terracciano; William D Foulkes
Journal:  Histopathology       Date:  2011-06-24       Impact factor: 5.087

5.  Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

Authors:  Alena Gros; Eric Tran; Maria R Parkhurst; Sadia Ilyas; Anna Pasetto; Eric M Groh; Paul F Robbins; Rami Yossef; Andrea Garcia-Garijo; Carlos A Fajardo; Todd D Prickett; Li Jia; Jared J Gartner; Satyajit Ray; Lien Ngo; John R Wunderllich; James C Yang; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

6.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.

Authors:  Chen Zhu; Ana C Anderson; Anna Schubart; Huabao Xiong; Jaime Imitola; Samia J Khoury; Xin Xiao Zheng; Terry B Strom; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2005-11-13       Impact factor: 25.606

7.  The role of B7 costimulation in CD4/CD8 T cell homeostasis.

Authors:  X Yu; S Fournier; J P Allison; A H Sharpe; R J Hodes
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

8.  PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Authors:  LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

Review 9.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

Review 10.  Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.

Authors:  Isabelle Le Mercier; J Louise Lines; Randolph J Noelle
Journal:  Front Immunol       Date:  2015-08-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.